ModerateCaution
Berberine inhibits CYP3A4 (and to a lesser extent CYP2D6), the same family of enzymes that fluconazole also inhibits. Stacking two CYP3A4 inhibitors can raise the systemic levels of co-prescribed CYP3A4 substrates (statins, calcium channel blockers, benzodiazepines, certain immunosuppressants) and prolong fluconazole's own half-life, increasing the risk of dose-related adverse effects such as hepatotoxicity and QT prolongation.
Recommendation: Avoid starting berberine during a fluconazole course. If you take berberine for blood sugar, hold it while on fluconazole and resume a few days after the course ends. Tell your prescriber about every CYP3A4 substrate you take.
ModerateCaution
Resveratrol inhibits CYP3A4 in vitro and in animal pharmacokinetic studies, where it has raised plasma exposure of CYP3A4 substrates such as nicardipine and ticagrelor. Layered on top of fluconazole's CYP3A4 and CYP2C9 inhibition, this could blunt clearance of other prescription medications metabolized by these enzymes.
Recommendation: Pause resveratrol supplementation during your fluconazole course, particularly if you also take statins, calcium channel blockers, anticoagulants, or benzodiazepines. Resume once fluconazole has cleared.
ModerateCaution
Quercetin inhibits CYP3A4 and P-glycoprotein in vitro and has altered the pharmacokinetics of CYP3A4 substrates in animal models. Used alongside fluconazole, which is itself a CYP3A4 and CYP2C9 inhibitor, quercetin may further reduce metabolism of co-prescribed drugs and prolong fluconazole exposure.
Recommendation: Avoid high-dose quercetin (more than ~500 mg/day) while on fluconazole, especially if you take a statin, calcium channel blocker, benzodiazepine, or anticoagulant. Resume after finishing the antifungal course.
ModerateCaution
Silymarin from milk thistle inhibits CYP3A4, CYP2C9, UGT enzymes, and P-glycoprotein in vitro, and clinical pharmacokinetic studies have shown modest interactions with substrates such as losartan and nifedipine. Because fluconazole itself inhibits CYP3A4 and CYP2C9, layering milk thistle may amplify suppression of drug metabolism while doing little to mitigate fluconazole hepatotoxicity risk in any RCT-proven way.
Recommendation: If you take milk thistle for liver support, discuss with your prescriber before continuing during fluconazole therapy. Do not rely on it to prevent fluconazole-induced liver injury; instead monitor liver enzymes as your prescriber advises.
ModerateCaution
Curcumin inhibits CYP3A4 and P-glycoprotein in vitro and has altered the pharmacokinetics of CYP3A4 substrates such as amlodipine and budesonide in animal studies. Combining curcumin supplements with fluconazole adds another inhibitor to the same metabolic pathway, which can raise levels of co-prescribed drugs metabolized by CYP3A4.
Recommendation: Pause concentrated curcumin or turmeric extract supplements during your fluconazole course. Culinary turmeric in food is fine. Resume supplementation a few days after finishing fluconazole.
SeriousConflict
St. John's Wort is a strong inducer of CYP3A4 (via PXR activation by hyperforin) and P-glycoprotein. Because fluconazole is partly metabolized by CYP3A4 and is itself a CYP3A4 inhibitor, St. John's Wort can lower fluconazole plasma levels and shorten its half-life, potentially leading to subtherapeutic exposure and treatment failure of a serious fungal infection.
Recommendation: Do not take St. John's Wort during fluconazole therapy. If you were already taking it, stop and tell your prescriber so they can consider monitoring response or extending the course.
ModerateSynergy
Fluconazole can prolong the QT interval, especially at higher doses, in renal impairment, or with other QT-prolonging drugs. Low magnesium and low potassium are independent, well-established risk factors for torsades de pointes. Keeping magnesium in the normal range reduces this background arrhythmia risk while you are taking fluconazole.
Recommendation: If your magnesium is low or you are on a diuretic, correct deficiency before starting fluconazole and maintain adequate intake during the course. Do not megadose; typical magnesium glycinate doses (200-350 mg elemental/day) are appropriate.
ModerateSynergy
Hypokalemia is a major risk factor for QT prolongation and torsades de pointes, and fluconazole independently prolongs the QT interval. Patients on diuretics, with GI losses, or with renal disease are especially vulnerable. Keeping potassium in the normal range reduces the arrhythmic risk of fluconazole therapy.
Recommendation: Have potassium checked before starting fluconazole if you take a diuretic, have vomiting/diarrhea, or have cardiac risk factors. Replace potassium as your clinician directs. Do not self-supplement high-dose potassium without labs.
InfoSynergy
Fluconazole can cause hepatotoxicity ranging from mild transaminase elevations to acute liver injury. N-acetylcysteine replenishes glutathione and has been studied as a treatment for non-acetaminophen drug-induced liver injury, with some evidence of benefit. The combination is not a substitute for liver monitoring but is a low-risk antioxidant strategy in higher-risk patients.
Recommendation: If you are at elevated risk of drug-induced liver injury (existing liver disease, alcohol use, polypharmacy), discuss NAC with your prescriber. Do not use NAC to mask the need for monitoring liver enzymes during fluconazole therapy.
SeriousCaution
Fluconazole is hepatotoxic in a dose- and duration-dependent fashion, and alcohol is one of the strongest modifiable risk factors for drug-induced liver injury. Drinking during fluconazole therapy meaningfully raises the chance of transaminase elevation, cholestasis, or symptomatic hepatitis, particularly with longer courses or repeated exposures.
Recommendation: Avoid alcohol while taking fluconazole and for several days after the course ends. If you must drink, keep it to one occasion and minimize quantity, and tell your prescriber so liver enzymes can be checked.
ModerateConflict
Saccharomyces boulardii is itself a yeast (a non-pathogenic strain of S. cerevisiae). Fluconazole has variable activity against Saccharomyces species and may suppress S. boulardii during therapy, defeating its probiotic purpose. Rare cases of S. boulardii fungemia have occurred in immunocompromised or central-line patients, where antifungal activity is desirable.
Recommendation: Hold Saccharomyces boulardii during your fluconazole course. Resume a few days after finishing fluconazole if you still want probiotic support. Lactobacillus-based probiotics are unaffected by fluconazole.
NutriStack